Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recommendations to address respondent burden associated with patient-reported outcome assessment.
Aiyegbusi OL, Cruz Rivera S, Roydhouse J, Kamudoni P, Alder Y, Anderson N, Baldwin RM, Bhatnagar V, Black J, Bottomley A, Brundage M, Cella D, Collis P, Davies EH, Denniston AK, Efficace F, Gardner A, Gnanasakthy A, Golub RM, Hughes SE, Jeyes F, Kern S, King-Kallimanis BL, Martin A, McMullan C, Mercieca-Bebber R, Monteiro J, Peipert JD, Quijano-Campos JC, Quinten C, Rantell KR, Regnault A, Sasseville M, Schougaard LMV, Sherafat-Kazemzadeh R, Snyder C, Stover AM, Verdi R, Wilson R, Calvert MJ. Aiyegbusi OL, et al. Among authors: regnault a. Nat Med. 2024 Mar;30(3):650-659. doi: 10.1038/s41591-024-02827-9. Epub 2024 Feb 29. Nat Med. 2024. PMID: 38424214 Review.
Emerging good practices for Translatability Assessment (TA) of Patient-Reported Outcome (PRO) measures.
Acquadro C, Patrick DL, Eremenco S, Martin ML, Kuliś D, Correia H, Conway K; International Society for Quality of Life Research (ISOQOL) Translation and Cultural Adaptation Special Interest Group (TCA-SIG). Acquadro C, et al. J Patient Rep Outcomes. 2017;2(1):8. doi: 10.1186/s41687-018-0035-8. Epub 2018 Feb 21. J Patient Rep Outcomes. 2017. PMID: 29757337 Free PMC article. Review.
Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer.
Regnault A, Bunod L, Loubert A, Brose MS, Hess LM, Maeda P, Lin Y, Speck RM, Gilligan AM, Payakachat N. Regnault A, et al. J Patient Rep Outcomes. 2024 Dec 19;8(1):149. doi: 10.1186/s41687-024-00823-8. J Patient Rep Outcomes. 2024. PMID: 39694978 Free PMC article. Clinical Trial.
Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study.
Sekeres MA, Santini V, Díez-Campelo M, Komrokji RS, Fenaux P, Savona MR, Madanat YF, Valcárcel-Ferreiras D, Oliva EN, Regnault A, Creel K, Sengupta N, Dougherty S, Shah S, Sun L, Wan Y, Navada S, Zeidan AM, Platzbecker U. Sekeres MA, et al. Among authors: regnault a. Leuk Lymphoma. 2024 Nov 13:1-6. doi: 10.1080/10428194.2024.2426057. Online ahead of print. Leuk Lymphoma. 2024. PMID: 39535901 Free article. No abstract available.
Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma.
Popat R, Lonial S, Voorhees PM, Esposti SD, Gorsh B, Gupta I, Opalinska J, Sapra S, Piontek T, He Z, Kleinman D, Schaumberg D, Regnault A, Meunier J, Eliason L. Popat R, et al. Among authors: regnault a. J Adv Pract Oncol. 2023 Sep;14(6):503-518. doi: 10.6004/jadpro.2023.14.6.4. Epub 2023 Sep 1. J Adv Pract Oncol. 2023. PMID: 37808071 Free PMC article.
98 results